ProBion

ProBion Innovation Sweden AB is a research-driven biotechnology company specializing in the development of high-viability probiotic therapies for clinical applications. The company's core innovation is the ProBion Matrix, a patented tablet technology that shields probiotic strains from moisture and gastric acids, ensuring over 80% viability and controlled release within the gastrointestinal tract. ProBion gained international recognition following a clinical trial published in BMJ Open Gastroenterology, which showed that its ProBion Clinica formulation could significantly alter the microbiome of colorectal cancer patients by reducing pathogenic bacteria. Headquartered in Sweden, the company continues to advance its pipeline of medical-grade probiotics targeting gastroenterological and oncological indications through rigorous scientific validation and academic collaborations.